Silver Book Fact

Effectiveness of pacemaker/defibrillators to control AFib

Widespread use of pacemaker/defibrillators to control atrial fibrillation could result in a 50% decrease in stroke.

Shekelle, Paul G., Eduardo Ortiz, Sydne J. Newberry, Michael W. Rich, Shannon L. Rhodes, Robert H. Brook, and Dana P. Goldman. Identifying Potential Health Care Innovations for the Elderly of the Future: Health and costs of the future elderly. Health Aff. 2005; 24(2). https://www.ncbi.nlm.nih.gov/pubmed/16186152

Reference

Title
Identifying Potential Health Care Innovations for the Elderly of the Future: Health and costs of the future elderly
Publication
Health Aff
Publication Date
2005
Authors
Shekelle, Paul G., Eduardo Ortiz, Sydne J. Newberry, Michael W. Rich, Shannon L. Rhodes, Robert H. Brook, and Dana P. Goldman
Volume & Issue
Volume 24, Issue 2
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Atrial fibrillation ablation prevents recurrence of AFib
    Atrial fibrillation ablation, which involves using a catheter inserted into the heart to destroy electrical conduction tissue in or near the atria, prevents the recurrence of atrial fibrillation in up…  
  • Stroke risk reduction from thrombin inhibitor in AFib patients
    A recently approved direct thrombin inhibitor was found to reduce the risk of stroke/peripheral embolic events in atrial fibrillation patients by 34%, and the risk of hemorrhagic stroke by 74%—compared…  
  • Per-patient annual cost of treating stroke in atrial fibrillation patients
    The per-patient annual cost of treating stroke in atrial fibrillation patients was found to be $1,485 in a wellcontrolled anti-coagulation clinic, $3,710 for those receiving warfarin in routine medical care,…  
  • Effect of optimal anticoagulation
    If 50% of atrial fibrillation patients who currently receive warfarin in routine medical care were optimally anticoagulated, 9,852 emboli would be prevented and $1.3 billion would be saved each year.  
  • Cost-savings associated with Warfarin use in AFib patients
    Warfarin use in Medicare patients with nonvalvular atrial fibrillation was independently associated with lower medical costs averaging $9,836 per patient, per year.